Mutations driving CLL and their evolution in progression and relapse

Nature

Volumn 526, Issue 7574, 2015, Pages 525-530

  Landau, Dan A ^a,b,c,d   Tausch, Eugen ^e   Taylor Weiner, Amaro N ^a   Stewart, Chip ^a   Reiter, Johannes G ^a,b,f,g   Bahlo, Jasmin ^h   Kluth, Sandra ^h   Bozic, Ivana ^g,i   Lawrence, Mike ^a   Böttcher, Sebastian ^j   Carter, Scott L ^a,c   Cibulskis, Kristian ^a   Mertens, Daniel ^e,k   Sougnez, Carrie L ^a   Rosenberg, Mara ^a   Hess, Julian M ^a   Edelmann, Jennifer ^e   Kless, Sabrina ^e   Kneba, Michael ^j   Ritgen, Matthias ^j   Fink, Anna ^h   Fischer, Kirsten ^h   Gabriel, Stacey ^a   Lander, Eric S ^a   Nowak, Martin A ^g,i   Döhner, Hartmut ^e   Hallek, Michael ^h,l   Neuberg, Donna ^b   Getz, Gad ^a,m   Stilgenbauer, Stephan ^e   Wu, Catherine J ^a,b,c,d   more..

^a BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF ULM   (Germany)

^f INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA   (Austria)

^g HARVARD UNIVERSITY   (United States)

^h UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

ⁱ HARVARD UNIVERSITY   (United States)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^l UNIVERSITY OF COLOGNE   (Germany)

^m MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DNA; FLUDARABINE; MYC PROTEIN; RITUXIMAB; IKAROS TRANSCRIPTION FACTOR; IKZF3 PROTEIN, HUMAN; RIBOSOMAL PROTEIN S21; RIBOSOME PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; DATA SET; DISEASE; DNA; GENETIC ANALYSIS; MUTATION; RNA; TUMOR;

ARTICLE; CANCER GROWTH; CHRONIC LYMPHATIC LEUKEMIA; CLL GENE; CLONAL EVOLUTION; CLONAL VARIATION; COPY NUMBER VARIATION; EXOME; GENE MUTATION; HUMAN; INDEL MUTATION; LEUKEMIA RELAPSE; MAJOR CLINICAL STUDY; NONSENSE MUTATION; PRIORITY JOURNAL; RNA PROCESSING; SOMATIC MUTATION; TUMOR GENE; CELL CLONE; CELL TRANSFORMATION; DISEASE COURSE; GENETICS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; METABOLISM; MOLECULAR EVOLUTION; MUTATION; ONCOGENE MYC; PATHOLOGY; PROGNOSIS; RNA TRANSPORT; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; TUMOR RECURRENCE;

CELL TRANSFORMATION, NEOPLASTIC; CLONE CELLS; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; EVOLUTION, MOLECULAR; EXOME; GENES, MYC; HUMANS; IKAROS TRANSCRIPTION FACTOR; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MAP KINASE SIGNALING SYSTEM; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RIBOSOMAL PROTEINS; RNA PROCESSING, POST-TRANSCRIPTIONAL; RNA TRANSPORT; TREATMENT OUTCOME;

EID: 84945302209     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature15395     Document Type: Article

References (40)

1. Quesada, V. et al. Exome sequencing identifies recurrentmutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia. Nature Genet. 44, 47-52 (2012).
2. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
3. Landau, D. A. et al. Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell 152, 714-726 (2013).
4. Schuh, A. et al. Monitoring chronic lymphocytic leukemia progression by whole genome sequencing reveals heterogeneous clonal evolution patterns. Blood 120, 4191-4196 (2012).
5. Lawrence, M. S. et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505, 495-501 (2014).
6. Hallek, M. et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376, 1164-1174 (2010).
7. Lawrence, M. S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
8. Edelmann, J. et al. High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations. Blood 120, 4783-4794 (2012).
9. De Paoli, L. et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk. Lymphoma 54, 1087-1090 (2013).
10. Schlosser, I. et al. Dissection of transcriptional programmes in response to serum and c-Myc in a human B-cell line. Oncogene 24, 520-524 (2005).
11. Jiang, X. et al. Critical role of SHP2 (PTPN11) signaling in germinal center-derived lymphoma. Haematologica 99, 1834-1845 (2014).
12. Zhang, J. & Chen, Q. M. Far upstreamelement binding protein 1: a commander of transcription, translation and beyond. Oncogene 32, 2907-2916 (2013).
13. Tiacci, E. et al. BRAF mutations in hairy-cell leukemia. N. Engl. J. Med. 364, 2305-2315 (2011).
14. Brastianos, P. K. et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genet. 46, 161-165 (2014).
15. Heidorn,S. J. et al. Kinase-deadBRAF andoncogenicRAS cooperate to drive tumor progression through CRAF. Cell 140, 209-221 (2010).
16. Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell 159, 676-690 (2014).
17. Yang, H. et al. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models. Cancer Res. 70, 5518-5527 (2010).
18. Jebaraj, B. M. et al. BRAF mutations in chronic lymphocytic leukemia. Leuk. Lymphoma 54, 1177-1182 (2013).
19. Landau, D. A. & Wu, C. J. Chronic lymphocytic leukemia: molecular heterogeneity revealed by high-throughput genomics. Genome Med. 5, 47 (2013).
20. Sashida, G. et al. ELF4/MEF activates MDM2 expression and blocks oncogeneinduced p16 activation to promote transformation. Mol. Cell. Biol. 29, 3687-3699 (2009).
21. Park, J. et al. Dyrk1A phosphorylates p53 and inhibits proliferation of embryonic neuronal cells. J. Biol. Chem. 285, 31895-31906 (2010).
22. Gazda,H.T. et al. Ribosomal proteinL5andL11mutations are associatedwithcleft palate and abnormal thumbs in Diamond-Blackfan anemia patients. Am. J. Hum. Genet. 83, 769-780 (2008).
23. Ferreiros-Vidal, I. et al. Genome-wide identification of Ikaros targets elucidates its contribution to mouse B-cell lineage specification and pre-B-cell differentiation. Blood 121, 1769-1782 (2013).
24. Billot, K. et al.Deregulation ofAiolos expression in chronic lymphocytic leukemia is associated with epigenetic modifications. Blood 117, 1917-1927 (2011).
25. Nückel, H. et al. The IKZF3 (Aiolos) transcription factor is highly upregulated and inversely correlated with clinical progression in chronic lymphocytic leukaemia. Br. J. Haematol. 144, 268-270 (2009).
26. Beà, S. et al. Genetic imbalances in progressed B-cell chronic lymphocytic leukemia and transformed large-cell lymphoma (Richter's syndrome). Am. J. Pathol. 161, 957-968 (2002).
27. Carter, S. L. et al. Absolute quantification of somatic DNA alterations in human cancer. Nature Biotechnol. 30, 413-421 (2012).
28. Papaemmanuil, E. et al. Clinical and biological implications of drivermutations in myelodysplastic syndromes. Blood 122, 3616-3627 (2013).
29. Wang, J. et al. Tumor evolutionary directed graphs and the history of chronic lymphocytic leukemia. Elife 3 (2014).
30. Stilgenbauer, S. et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results fromthe CLL8 trial. Blood 123, 3247-3254 (2014).
31. Rossi, D. et al. Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. Blood 121, 1403-1412 (2013).
32. Damm, F. et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. Cancer Discov. 4, 1088-1101 (2014).
33. Winkelmann, N. et al. Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Haematologica 100, e237-e239 (2015).
34. Puente, X. S. & Lopez-Otin, C. The evolutionary biography of chronic lymphocytic leukemia. Nature Genet. 45, 229-231 (2013).
35. Nowak,M. A. et al. The role of chromosomal instability in tumor initiation. Proc. Natl Acad. Sci. USA 99, 16226-16231 (2002).
36. Bozic, I. et al. Accumulation of driver and passenger mutations during tumor progression. Proc. Natl Acad. Sci. USA 107, 18545-18550 (2010).
37. Davoli, T. et al.Cumulative haploinsufficiency and triplosensitivity driveaneuploidy patterns and shape the cancer genome. Cell 155, 948-962 (2013).
38. Hallek, M. Chronic lymphocytic leukemia: 2015 Update on diagnosis, risk stratification, and treatment. Am. J. Hematol. 90, 446-460 (2015).
39. Alexandrov, L. B. et al. Signatures ofmutational processes in human cancer. Nature 500, 415-421 (2013).
40. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).